APA (7th ed.) Citation

Mugnier, L., Espitalier, F., Menegotto, J., Bell, S., & Ré, M. I. (2023). Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer. Pharmaceutical Development & Technology, 28(7), 697. https://doi.org/10.1080/10837450.2023.2233612

Chicago Style (17th ed.) Citation

Mugnier, L., F. Espitalier, J. Menegotto, S. Bell, and M. I. Ré. "Solid Amorphous Formulations for Enhancing Solubility and Inhibiting Erlotinib Crystallization During Gastric-to-intestinal Transfer." Pharmaceutical Development & Technology 28, no. 7 (2023): 697. https://doi.org/10.1080/10837450.2023.2233612.

MLA (9th ed.) Citation

Mugnier, L., et al. "Solid Amorphous Formulations for Enhancing Solubility and Inhibiting Erlotinib Crystallization During Gastric-to-intestinal Transfer." Pharmaceutical Development & Technology, vol. 28, no. 7, 2023, p. 697, https://doi.org/10.1080/10837450.2023.2233612.